China Health Resource Announces Professor Liang Li, World Renowned TCM Expert, to Lead Gastrodia Deep Processing Research

SHANGHAI, January 31, 2012 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: CHRI), announced today that world renowned Traditional Chinese Medicine expert, Professor Liang Li, has been engaged to lead the Company's Gastrodia Deep Processing Research. The research initiative is focused on optimizing yields from raw Gastrodia and to find new potential uses of Gastrodia using deep processing.

Professor Liang Li, age 73, is currently a member of the State Modernization of Chinese Medicine Technology Industry (Sichuan) Base Expert Committee. He is also Professor Director of the Institute of Chinese Medicine in Mianyang City. Professor Li is currently employed by Tailing Bio Technology Co., Ltd as technology director; Chief Editor of "National TCM Herbal GAP Guide." He participated in the world's traditional medicine event in Las Vegas, USA (Vitality Cup) and received the Gold award for best paper. His current focus is now in "Modernization of Chinese traditional medicine research and industrial development" & "Sichuan TCM origin Gastrodia planting standardized research" projects. He prepared the "Gastrodia ('TianMa') standardized planting procedure" (GAP).

"We are very excited at having Professor Liang Li lead our Gastrodia research. He is a highly accomplished and well known scientist in TCM," stated Jiayin Wang, Chairman and CEO of CHRI. "Gastrodia is known by name by many but little scientific research has been devoted to it. Professor Li is one of the few experts worldwide in Gastrodia. Gastrodia has not received the level of research it deserves and we intend to take advantage of this opportunity. It is undervalued as a healthcare component and CHRI is planning to capitalize on this fact just as we did by creating a franchise in GAP DAR before others and making us a recognized leader in DAR," added Mr. Wang.

About CHRI

China Health Resource, Inc. engages in the development, manufacturing, processing, marketing and sale of raw and pharmaceutical TCM products including Dahurian Angelica Root (DAR) and Rhizoma Gastrodiae and is only the provider of GAP quality DAR in the People's Republic of China under the registered Trademark Chuan Baizhi™. DAR, which is also known as "Bai Zhi" in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The Company's DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The Company was founded in 2001 and is based in Suining, Sichuan Province.

For more information refer to www.chinahealthresource.com.

Certain statements in this document regarding financial matters, other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.

Related stocks: OTC:CHRI